Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis

PURPOSE: Two randomized trials published in 2001 provided level 1 evidence for the use of cytoreductive nephrectomy (CyNx) for the treatment of metastatic renal cell carcinoma (mRCC). However, the regulatory approval of vascular endothelial growth factor tyrosine kinase inhibitors (VEGFR-TKI) in 200...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:World J Urol
Auteurs principaux: Tsao, Che-kai, Small, Alexander C., Kates, Max, Moshier, Erin L., Wisnivesky, Juan P., Gartrell, Benjamin A., Sonpavde, Guru, Godbold, James H., Palese, Michael A., Hall, Simon J., Oh, William K., Galsky, Matthew D.
Format: Artigo
Langue:Inglês
Publié: 2012
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4744480/
https://ncbi.nlm.nih.gov/pubmed/23223962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00345-012-1001-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires